Erasca reports 40% response rate in NRAS Q61X melanoma cohort from Phase 1b SEACRAFT-1 trial

Erasca, Inc.

40% (4/10) response rate in efficacy-evaluable NRAS Q61X melanoma patients; 3 confirmed partial responses, 1 unconfirmed.
70% (7/10) of patients remained on treatment as of September 5, 2024 efficacy cutoff.
Mandatory primary rash prophylaxis reduced skin toxicities and drug discontinuation rate vs. prior Novartis trials.
Company expects SEACRAFT-2 Phase 3 randomized dose optimization data readout in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.